Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Chikako Setoguchi is active.

Publication


Featured researches published by Chikako Setoguchi.


European Journal of Pharmacology | 2008

SA13353 (1-[2-(1-Adamantyl)ethyl]-1-pentyl-3-[3-(4-pyridyl)propyl]urea) inhibits TNF-α production through the activation of capsaicin-sensitive afferent neurons mediated via transient receptor potential vanilloid 1 in vivo

Masaaki Murai; Fumio Tsuji; Masafumi Nose; Iwao Seki; Kenji Oki; Chikako Setoguchi; Hiroshi Suhara; Minoru Sasano; Hiroyuki Aono

Tumor necrosis factor-alpha (TNF-alpha) is known to play a crucial role in the pathogenesis of rheumatoid arthritis. In the present study, we demonstrate the effects of SA13353 (1-[2-(1-Adamantyl)ethyl]-1-pentyl-3-[3-(4-pyridyl)propyl]urea), a novel orally active inhibitor of TNF-alpha production, in animal models, and its mechanism of action on TNF-alpha production. SA13353 significantly inhibited lipopolysaccharide (LPS)-induced TNF-alpha production in a dose-dependent manner in rats. Moreover, SA13353 exhibited a binding affinity for the rat vanilloid receptor and increased neuropeptide release from the rat dorsal root ganglion neurons. However, its effects were blocked by pretreatment with the transient receptor potential vanilloid 1 (TRPV1) antagonist capsazepine. The ability of SA13353 and capsaicin to inhibit LPS-induced TNF-alpha production was eliminated by sensory denervation or capsazepine pretreatment in vivo. Although they inhibited LPS-induced TNF-alpha production in mice, these effects were not observed in TRPV1 knockout mice. SA13353 provoked the release of neuropeptides without nerve inactivation, even when chronically administered to rats. These results suggest that SA13353 inhibits TNF-alpha production through activation of capsaicin-sensitive afferent neurons mediated via TRPV1 in vivo. Post-onset treatment of SA13353 strongly reduced the hindpaw swelling and joint destruction associated with collagen-induced arthritis in rats. Thus, SA13353 is expected to be a novel anti-arthritic agent with a unique mechanism of action.


Investigative Ophthalmology & Visual Science | 2014

Impact of P-Glycoprotein on Blood–Retinal Barrier Permeability: Comparison of Blood–Aqueous Humor and Blood–Brain Barrier Using Mdr1a Knockout Rats

Shinobu Fujii; Chikako Setoguchi; Kouichi Kawazu; Ken-ichi Hosoya

PURPOSE The purpose of this study was to clarify the impact of P-glycoprotein (P-gp) on blood-retinal barrier (BRB) and blood-aqueous humor barrier (BAB) permeability, in contrast to blood-brain barrier (BBB) permeability. METHODS Permeabilities of six compounds, including P-gp substrates (quinidine, digoxin, and verapamil), were investigated in wild-type and mdr1a knockout rats using retinal, aqueous humor, and brain uptake index (RUI, AHUI, and BUI, respectively) methods and integration plot analysis. RESULTS In both rat strains, quinidine, digoxin, and verapamil were transported by P-gp across each barrier; however, the impact of P-gp on retinal uptake of quinidine and verapamil was less pronounced than that on brain uptake. The apparent influx permeability clearance (Kin) values of verapamil in retina obtained from wild-type and knockout rats were similar (0.824 ± 0.201 and 0.849 ± 0.980 mL/min·g retina, respectively; mean ± SD; n = 3 rats). The Kin in aqueous humor and brain obtained from knockout rats was, respectively, 3-fold and 12-fold higher than that of wild-type (P < 0.05). In P-gp-deficient conditions, the RUI and AHUI of quinidine, digoxin, and verapamil, as well as the BUI of quinidine and digoxin, were decreased by P-gp inhibitors. However, the BUI of verapamil was not changed by P-gp inhibitors. Results suggest that carrier-mediated influx transporters exist in the blood-ocular barriers and that the function of verapamil influx transporters is markedly different between the retina and brain. CONCLUSIONS In both rat strains, P-gp operates in the blood-ocular barriers, and the impact of P-gp on BRB permeability to quinidine and verapamil is lower than that on BBB permeability.


International Journal of Immunopharmacology | 1993

Restorative effect of short term administration of thymulin on thymus-dependent antibody production in restraint-stressed mice.

Masahiro Okamoto; Masataka Morishita; Chikako Setoguchi; Katsuhiko Nakata

Thymulin is a well defined nonapeptide produced by thymic epithelial cells, and plays an important role in thymocyte differentiation. We investigated the restorative effect of thymulin on the stress-induced reduction in the production of antibodies against SRBC in mice. Antibody production in stressed mice was reduced to about 50% of that in normal mice. A 3-day period of administration of thymulin (1 ng/kg) restored antibody production to close to the normal level, whereas thymulin (1 ng-1 microgram/kg) did not affect antibody production in normal mice. These results indicated that thymulin normalizes the altered thymus-dependent immune responses.


Drug Metabolism and Disposition | 2015

Functional Characterization of Carrier-Mediated Transport of Pravastatin across the Blood-Retinal Barrier in Rats

Shinobu Fujii; Chikako Setoguchi; Kouichi Kawazu; Ken-ichi Hosoya

Systemically administered pravastatin effectively treats diabetic retinopathy without central nervous system side effects. The efflux transport mechanism of pravastatin from the brain has already been clarified. In this study, the influx of pravastatin across the blood-retinal and blood-brain barriers (BRB and BBB) and the efflux of pravastatin from the retina were investigated using rats. Pravastatin influx (blood-to-tissues) was assessed using the retinal and brain uptake index (RUI and BUI) methods, and microdialysis was performed to investigate the efflux (retina-to-blood) transport of pravastatin. The RUI and BUI values for [3H]pravastatin were lower than those expected based on its lipophilicity, suggesting that the influx transport across the BRB and BBB was less than the reverse-direction transport. The RUI and BUI values for [3H]pravastatin were significantly decreased by pravastatin, digoxin, and probenecid, indicating that pravastatin undergoes carrier-mediated influx transport in the blood-to-tissues direction across the BRB and BBB. After intravitreal injection, [3H]pravastatin and the bulk flow marker [14C]d-mannitol were found to be eliminated biexponentially from the vitreous humor. The elimination rate constant of [3H]pravastatin during the terminal phase was 1.66-fold greater than that of [14C]d-mannitol. Efflux transport was reduced in the retinal presence of pravastatin, digoxin, and benzylpenicillin, suggesting that pravastatin is transported via efflux transporters. In conclusion, pravastatin is transported across the BRB via uptake and efflux transporters in both the blood-to-retina and retina-to-blood directions, and the retina-to-blood transporters are dominant, based on the lower values of the RUI compared with the values expected from the lipophilicity


Bioorganic & Medicinal Chemistry Letters | 2010

Synthesis and pharmacological evaluation of 1,1,3-substituted urea derivatives as potent TNF-α production inhibitors

Hiroshi Enomoto; Ayako Sawa; Hiroshi Suhara; Noriyoshi Yamamoto; Hiroyuki Inoue; Chikako Setoguchi; Fumio Tsuji; Masahiro Okamoto; Yoshimasa Sasabuchi; Masato Horiuchi; Masakazu Ban

A three substituted urea derivative, SA13353 (compound 1a), exhibited potent inhibitory activity against lipopolysaccharide (LPS)-induced TNF-alpha production. We focused on the 1,1-substituted moiety (R(1) and R(2)) of SA13353 and investigated substituent effects of this moiety on LPS-induced TNF-alpha production by oral administration in rats. The synthesis of the urea derivatives was performed rapidly in a one-pot manner using a manual synthesizer. Several compounds containing hydrophobic substituents at this moiety showed more potent inhibitory activities than SA13353.


International Immunopharmacology | 2012

Bucillamine inhibits CD40-mediated Akt activation and antibody production in mouse B-cell lymphoma.

Fumio Tsuji; Chikako Setoguchi; Masahiro Okamoto; Iwao Seki; Minoru Sasano; Hiroyuki Aono

The improvement of rheumatoid factor titers in patients with rheumatoid arthritis is one of the significant clinical effects of bucillamine (Buc). In this study, we investigated the effects of SA981, an active metabolite of Buc, and methotrexate (MTX) on CD40-mediated antibody production using mouse B-cell lymphoma, BCL1. SA981 significantly attenuated CD40-mediated antibody production in a concentration-dependent manner, but weakly affected cell proliferation. In contrast, MTX did not attenuate CD40-mediated antibody production until it had strongly inhibited cell proliferation at a concentration of 100 nM. CD40 signaling induced protein phosphorylation, including Akt phosphorylation, p38 mitogen-activated protein kinase (p38MAPK), and IκBα. SA981 at a concentration of 30 μM attenuated CD40-mediated Akt phosphorylation, but not p38MAPK or IκBα phosphorylation. MTX at a concentration of 100 nM did not affect CD40-mediated Akt, p38MAPK, or IκBα phosphorylation. Commercially available Akt inhibitor VIII significantly attenuated CD40-mediated IgM production at a concentration of 100 nM without significant inhibition of cell proliferation. These results suggest that SA981 inhibits CD40-mediated antibody production in mouse B-cell lymphoma, at least in part, by attenuation of Akt phosphorylation.


Ensho Saisei | 1997

Effects of salazosulfapyridine and bucillamine on the active Arthus reaction and delayed-type hypersensitivity response.

Noriko Odani; Chikako Setoguchi; Minoru Sasano

Effects of salazosulfapyridine (SASP) and bucillamine (Bc), as disease-modifying antirheumatic drugs (DMARDs), on an active Arthus reaction and a delayed-type hypersensitivity (DTH) response were studied. SASP and Bc significantly suppressed the active Arthus reaction and DTH response. SASP and Bc also increased some cytokines in the DTH mice serum, such as interferon (IFN) -γ, interleukin (IL) -4, and IL-10.These results suggest that SASP and Bc activate all types of T cells, especially Th0 and Th2 involved in type IV (delayed-type) hypersensitivity, and also suppress type III hypersensitivity activated with immune complex.


Modern Rheumatology | 2010

Combined effects of bucillamine and etanercept on a rat type II collagen-induced arthritis model

Chikako Setoguchi; Fumio Tsuji; Osamu Katsuta; Masahiro Okamoto; Hiroyuki Aono


Archive | 2003

Therapeutic agent for rheumatism containing benzamide derivative as active ingredient

Hiroyuki Aono; Masahiro Okamoto; Miwa Takai; Chikako Setoguchi


Archive | 2005

Therapeutic agent for rheumatic disease comprising benzamide derivative as active ingredient

Hiroyuki Aono; Masahiro Okamoto; Miwa Takai; Chikako Setoguchi

Collaboration


Dive into the Chikako Setoguchi's collaboration.

Top Co-Authors

Avatar

Fumio Tsuji

SANTEN PHARMACEUTICAL CO.

View shared research outputs
Top Co-Authors

Avatar

Hiroyuki Aono

SANTEN PHARMACEUTICAL CO.

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Minoru Sasano

SANTEN PHARMACEUTICAL CO.

View shared research outputs
Top Co-Authors

Avatar

Iwao Seki

SANTEN PHARMACEUTICAL CO.

View shared research outputs
Top Co-Authors

Avatar

Kenji Oki

SANTEN PHARMACEUTICAL CO.

View shared research outputs
Top Co-Authors

Avatar

Masaaki Murai

SANTEN PHARMACEUTICAL CO.

View shared research outputs
Top Co-Authors

Avatar

Hiroshi Suhara

SANTEN PHARMACEUTICAL CO.

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kouichi Kawazu

SANTEN PHARMACEUTICAL CO.

View shared research outputs
Researchain Logo
Decentralizing Knowledge